Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2)

被引:13
作者
Eichelberger, MC
Sperber, E
Wagner, M
Hoshino, Y
Dudas, R
Hodgins, V
Marron, J
Nehring, P
Casey, R
Burns, B
Karron, R
Clements-Mann, ML
Kapikian, AZ
机构
[1] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ, Sch Publ Hlth, Dept Int Hlth, Ctr Immunizat Res, Baltimore, MD USA
关键词
rotavirus; clinical trials; vaccine;
D O I
10.1002/jmv.2160
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The safety, infectivity, and immunogenicity of two human-bovine reassortant rotavirus candidate vaccines were evaluated in adults, children, and infants. One of these, Wa x UK, contained a single human rotavirus gene from the Wa strain that encoded VP4 P1A specificity in a background of 10 bovine genes including the VP7 gene that encodes G6 specificity, whereas the other, Wa x (DS-1 x UK), possessed the human rotavirus VP4 gene from the Wa strain as well as the human VP7 gene from strain DS-1 that encoded G2 specificity. Each of these vaccines appeared to be well-tolerated and immunogenic in infants less than 6 months of age following a single oral dose, and therefore should be evaluated further as vaccine candidates. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:407 / 416
页数:10
相关论文
共 33 条
[1]  
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[2]   Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate [J].
Barnes, GL ;
Lund, JS ;
Adams, L ;
Mora, A ;
Mitchell, SV ;
Caples, A ;
Bishop, RF .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1997, 33 (04) :300-304
[3]   Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].
Bernstein, DI ;
Sack, DA ;
Rothstein, E ;
Reisinger, K ;
Smith, VE ;
O'Sullivan, D ;
Spriggs, DR ;
Ward, RL .
LANCET, 1999, 354 (9175) :287-290
[4]   EVALUATION OF WC3 ROTAVIRUS VACCINE AND CORRELATES OF PROTECTION IN HEALTHY INFANTS [J].
BERNSTEIN, DI ;
SMITH, VE ;
SANDER, DS ;
PAX, KA ;
SCHIFF, GM ;
WARD, RL .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1055-1062
[5]  
*CDC, 1999, MMWR-MORBID MORTAL W, V48, P1007
[6]  
Centers for Disease Control and Prevention (CDC), 1999, MMWR-MORBID MORTAL W, V48, P577
[7]  
Clark HF, 1996, ARCH VIROL, P187
[8]   Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants [J].
Clements-Mann, ML ;
Makhene, MK ;
Mrukowicz, J ;
Wright, PF ;
Hoshino, Y ;
Midthun, K ;
Sperber, E ;
Karron, R ;
Kapikian, AZ .
VACCINE, 1999, 17 (20-21) :2715-2725
[9]   Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants [J].
Clements-Mann, ML ;
Dudas, R ;
Hoshino, Y ;
Nehring, P ;
Sperber, E ;
Wagner, M ;
Stephens, I ;
Karron, R ;
Deforest, A ;
Kapikian, AZ .
VACCINE, 2001, 19 (32) :4676-4684
[10]  
DEMOL P, 1986, LANCET, V2, P108